Metformin controlled-release/sitagliptin - Merck

Drug Profile

Metformin controlled-release/sitagliptin - Merck

Alternative Names: Januet XR; Janumet XR; MK-0431A XR; Sitagliptin/metformin HCl extended-release; Sitagliptin/metformin hydrochloride extended-release

Latest Information Update: 31 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck & Co
  • Class Antihyperglycaemics; Biguanides; Insulin sensitisers; Pyrazines; Small molecules; Triazoles
  • Mechanism of Action AMP activated protein kinase stimulants; CD26 antigen inhibitors; Gluconeogenesis inhibitors; Glucose modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 31 Aug 2017 Phase-III development for Type-2 diabetes mellitus (In adolescents, In children) is ongoing in countries worldwide (PO) (NCT01760447) (EudraCT2012-004035-23)
  • 31 Aug 2017 Phase-III clinical trials in Type-2 diabetes mellitus (In adolescents, In children) in Moldova, Mauritius, Greece, Guatemala and Georgia (PO) before August 2017 (NCT01760447)
  • 07 Apr 2017 Merck receives complete response letter from the FDA for metformin controlled-release/sitagliptin treatment of patients with Type 2 diabetes mellitus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top